New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTVVUS, OREX, ARNAVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 17, 2015
08:45 EDTOREXOrexigen management to meet with Leerink
Subscribe for More Information
June 16, 2015
19:01 EDTARNAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Bob Evans (BOBE), up 4%. ALSO HIGHER: Anthera Pharmaceuticals (ANTH), up 2.4% after meeting enrollment targets of Phase 3 clinical trial evaluating blisibimod. DOWN AFTER EARNINGS: DavidsTea (DTEA), down 10.8%... La-Z-Boy (LZB), down 3.9%... Adobe (ADBE), down 1.2%. ALSO LOWER: Azure Midstream Partners (AZUR), down 8.5% after announcing that it will offer 3.5M common units... Arena Pharmaceuticals (ARNA), down 2.3% after announcing CFO departure.
16:32 EDTARNAArena Pharmaceuticals announces departure of CFO
Arena Pharmaceuticals announced that Robert Hoffman, SVP, Finance and CFO, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry. Hoffman is expected to remain in his current role at Arena until July 10. Following Hoffman's departure, Jennifer Bielasz, Arena's VP, Accounting and Controller, will continue to play a key leadership role in Arena's finance department.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use